Skip to content

Author

M. El-Tanani

We have 12 of 249 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Open access Nov 2026

The synthetic biology frontier: engineered oncolytic viruses and viral vectors for next-generation cancer therapy and gene delivery

Viruses are no longer used merely as naturally occurring tools for gene transfer or as blunt cytolytic agents. Researchers are rewriting their genomes, capsids, tropisms, regulatory elements, and payloads to create therapeutic systems that sense disease, execute conditional programs, and remodel pathological tissue. In...

Rawan H. Alsharedeh, Alaa A. A. Aljabali, Mohammad A. Obeid et al. · 0 citations
Review Open access Oct 2026

Oxidative Stress in the Pathophysiology of Chronic and Diabetic Kidney Disease: Molecular Mechanisms, Biomarkers, and Antioxidant Therapeutic Strategies

Despite considerable breakthroughs in renoprotective medicines, chronic kidney disease (CKD) and diabetic kidney disease (DKD) remain the predominant causes of end-stage renal disease and cardiovascular morbidity. Growing evidence shows that oxidative stress is not simply a result of renal injury but a crucial pathogen...

S. A. Rabbani, M. El-tanani, Rakesh Kumar et al. · 0 citations
Review Open access Oct 2026

Theranostic Imaging Agents: Integrating Molecular Diagnostics, Precision Therapeutics, and Artificial Intelligence

Theranostic imaging agents combine molecular diagnosis, targeted therapy and monitoring of treatment response into a single paradigm of precision medicine. This review summarizes the current development and translational landscape of theranostic imaging agents, covering molecular targets, imaging platforms, principles...

Shrestha Sharma, S. A. Rabbani, M. El-Tanani et al. · 0 citations
Review Open access Oct 2026

Diabesity: an old term, a modern challenge — multi-omics and precision anti-obesity pharmacotherapy in type 2 diabetes

Evidence for approved and investigational oral incretin therapies, dual and triple receptor agonists, amylin-based strategies, established antidiabetic drugs, and adjunctive approaches targeting body composition are summarized.

Karolina Hoffmann, Weronika Pucek, Wiktoria Skrzypek et al. · 0 citations
Review Open access Oct 2026

CAR T-Cell Therapy in Hematological Malignancies: Mechanisms, Innovations, and Challenges

Simple Summary Chimeric antigen receptor (CAR) T-cell therapy is a revolutionary immunotherapy that engineers a patient’s own immune T cells to specifically target and destroy malignant cells in hematological malignancies. This approach has transformed the treatment of relapsed acute lymphoblastic leukemia, lymphomas,...

Alaa A. A. Aljabali, Mohammad A. Obeid, A. Alqudah et al. · 0 citations
Review Open access Sep 2026

Effects of Dialysate Calcium Concentration on Bone, Mineral Metabolism, and Vascular Outcomes in Maintenance Hemodialysis: A Systematic Review and Meta-Analysis

Background/Objectives: The optimal dialysate calcium concentration in maintenance hemodialysis remains uncertain because reducing calcium exposure may limit calcium loading but can also stimulate parathyroid hormone secretion and impair intradialytic cardiovascular stability. We evaluated randomized evidence across bon...

I. Alabid, W. Alghoul, M. Abedi et al. · 0 citations
Review Open access Sep 2026

Targeting the Gut–Bone Axis with Prebiotics, Probiotics, Synbiotics, and Postbiotics: From Mechanistic Plausibility to Clinical Bone Outcomes

Osteoporosis is a major skeletal disorder. Increasing evidence suggests that gut microbiota-derived mechanisms may contribute to bone remodeling. The biological rationale for a gut–bone axis is well supported, but the clinical relevance of microbiome-targeted interventions remains uncertain. In this narrative review, w...

Sorina Ispas, V. Maggio, A. Wali et al. · 0 citations
Review Open access Sep 2026

From Neonatal History to Adult Cardiovascular Risk: Preterm Birth as a Lifelong Risk Enhancer

Background: Preterm birth is increasingly recognized as an early-life exposure with potential cardiovascular consequences across the lifespan. Although improved neonatal care has increased survival among individuals born very and extremely preterm, birth history remains rarely incorporated into cardiovascular risk asse...

M. Patni, Malek Nasrallah, D. J. Al Tarawneh et al. · 0 citations
Review Open access Jan 2026

Microbiome‐Driven Mechanisms in Breast Cancer: Emerging Evidence From Gut Microbial Signatures to Therapeutic Response

Current preclinical and clinical evidence describing the gut–breast cancer axis and its mechanistic and translational relevance is summarized and current advances in microbiome‐targeted interventions including probiotics, dietary modulation, postbiotics, and fecal microbiota transplantation are discussed.

A. Wali, Sirajunisa Talath, I. Rangraze et al. · 0 citations
Review Open access Sep 2026

Bioinspired and Biomimetic Nanocarriers: Advances in Exosomes and Cell-Membrane-Coated Systems for Therapeutic Applications

Abstract The translation of nanomedicine from bench to bedside has been thwarted by the limitations of conventional synthetic nanoparticles including rapid mononuclear phagocyte system (MPS) clearance, lack of target specificity, immunogenicity and poor intracellular delivery. To overcome these limitations, bioinspired...

M. El-Tanani, S. A. Rabbani, A. Wali et al. · 0 citations
Review Open access Sep 2026

Pathological Complete Response to Nab-Paclitaxel–Containing Neoadjuvant Regimens in Early Triple-Negative Breast Cancer: A Systematic Review and Meta-Analysis

Within nab-paclitaxel-containing neoadjuvant backbones, checkpoint-inhibitor addition was associated with higher pCR in randomized comparative evidence, and should not be interpreted as a cross-regimen comparison because of clinical and methodological heterogeneity.

R. A. Salama, M. El-Tanani, S. A. Rabbani et al. · 0 citations
#explainable ai Review Open access Sep 2026

From surveillance to intelligence: a scoping review of machine learning for antimicrobial resistance surveillance intelligence across One Health

A One Health AMR Surveillance Intelligence Framework is proposed to organise this shift from data generation toward actionable, adaptive surveillance intelligence, and the evidence demonstrates technical feasibility far more convincingly than operational readiness.

S. A. Rabbani, M. El-Tanani, I. Matalka et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.